NYSE:DNA

Ginkgo Bioworks Stock News

Healthcare > Biotechnology

Buy DNA

*Your capital is at risk

$7.89

-0.110 (-1.38%)

At Close: Jun 12, 2026

FTAI Aviation: Innovation Is Their DNA

08:52am, Sunday, 07'th Jun 2026

FTAI Aviation is innovatively leveraging jet engine cores to address the urgent power needs of data centers amid an energy bottleneck. FTAI's new power segment, repurposing CFM56 engines, could add 30

Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights

08:58am, Monday, 01'st Jun 2026

BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

08:15am, Friday, 29'th May 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA)

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

12:33pm, Tuesday, 26'th May 2026

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to m

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

04:05pm, Thursday, 21'st May 2026

Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further high

DNA X, Inc. Reports First Quarter 2026 Financial Results

05:00pm, Wednesday, 20'th May 2026

Closed sale of the Company's mobile device assets to NEXA in January 2026 Completed the transfer of the operations of the phone and hotspot business to NEXA Focused on enhancing the DNA X trading plat

DNA Finland Extends Fiber-Grade Connectivity to Lower-Density MDUs with Harmonic

03:00am, Tuesday, 19'th May 2026

Harmonic's SeaStar Optical Node Enables Cost-Effective Broadband Service Expansion in Previously Underserved Brownfield MDU Environments SAN JOSE, Calif., May 19, 2026 /PRNewswire/ -- Harmonic (NASDAQ

Ginkgo Bioworks: Another Lost Year

10:44am, Wednesday, 13'th May 2026

Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs bu

The $59B Quiet Shift Reshaping How Patients Access Care

11:00am, Tuesday, 12'th May 2026

The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026

Lotus Unveils Focus 2030 – Reinforcing Brand DNA with an All-New Hybrid-V8 Supercar

07:00pm, Monday, 11'th May 2026

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (“Lotus Tech” or the “Company”) (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced Focus

Ginkgo Bioworks Q1 Earnings Call Highlights

11:06pm, Saturday, 09'th May 2026

Ginkgo Bioworks NYSE: DNA said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in t

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

04:05pm, Thursday, 07'th May 2026

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA,

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by